Combination therapy of newly diagnosed intermediate-risk pulmonary arterial hypertension: A review
Advancements in the specific therapy of pulmonary arterial hypertension (PAH) and new combination therapy strategies and escalation treatment over the past decade have significantly improved disease control, slowed its progression, and improved quality of life and patient survival. This review provi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
ZAO "Consilium Medicum",
2022-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_1dba1c3c2f844ab0b5cf68f4fa15121d | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Irina N. Lyapina |e author |
| 700 | 1 | 0 | |a Tatiana N. Zvereva |e author |
| 700 | 1 | 0 | |a Tamila V. Martynyuk |e author |
| 245 | 0 | 0 | |a Combination therapy of newly diagnosed intermediate-risk pulmonary arterial hypertension: A review |
| 260 | |b ZAO "Consilium Medicum", |c 2022-12-01T00:00:00Z. | ||
| 500 | |a 2075-1753 | ||
| 500 | |a 2542-2170 | ||
| 500 | |a 10.26442/20751753.2022.10.201875 | ||
| 520 | |a Advancements in the specific therapy of pulmonary arterial hypertension (PAH) and new combination therapy strategies and escalation treatment over the past decade have significantly improved disease control, slowed its progression, and improved quality of life and patient survival. This review provides a detailed discussion of current strategies for PAH-specific therapy available in the Russian Federation for patients with classical and non-classical PAH who fail to achieve treatment goals and remain at intermediate risk of disease progression/mortality. | ||
| 546 | |a RU | ||
| 690 | |a pulmonary arterial hypertension | ||
| 690 | |a intermediate risk of mortality | ||
| 690 | |a pah-specific therapy | ||
| 690 | |a initial combination therapy | ||
| 690 | |a Medicine (General) | ||
| 690 | |a R5-920 | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Consilium Medicum, Vol 24, Iss 10, Pp 688-695 (2022) | |
| 787 | 0 | |n https://consilium.orscience.ru/2075-1753/article/viewFile/117537/92202 | |
| 787 | 0 | |n https://doaj.org/toc/2075-1753 | |
| 787 | 0 | |n https://doaj.org/toc/2542-2170 | |
| 856 | 4 | 1 | |u https://doaj.org/article/1dba1c3c2f844ab0b5cf68f4fa15121d |z Connect to this object online. |